Temozolomide (TMZ) is the standard of care chemotherapeutic agent used in the treatment of glioblastoma multiforme. Cytotoxic O6-methylguanine lesions formed by TMZ are repaired by O6-methyl-guanine DNA methyltransferase (MGMT), a DNA repair protein that removes alkyl groups located at the O6-position of guanine. Response to TMZ requires low MGMT expression and functional mismatch repair. Resistance to TMZ conferred by MGMT, and tolerance to O6-methylguanine lesions conferred by deficient MMR severely limit TMZ clinical applications. Therefore, development of new TMZ derivatives that can overcome TMZ-resistance is urgent. In this study, we investigated the anti-tumor mechanism of action of two novel TMZ analogs: C8-imidazolyl (377) and C8-methylimidazole (465) tetrazines. We found that analogs 377 and 465 display good anticancer activity against MGMT-overexpressing glioma T98G and MMR deficient colorectal carcinoma HCT116 cell lines with IC50 value of 62.50, 44.23, 33.09, and 25.37 μM, respectively. Analogs induce cell cycle arrest at G2/M, DNA double strand break damage and apoptosis irrespective of MGMT and MMR status. It was established that analog 377, similar to TMZ, is able to ring-open and hydrolyze under physiological conditions, and its intermediate product is more stable than MTIC. Moreover, DNA adducts of 377 with calf thymus DNA were identified: N7-methylguanine, O6-methylguanine, N3-methyladenine, N3-methylthymine, and N3-methylcytidine deoxynucleotides. We conclude that C8 analogs of TMZ share a mechanism of action similar to TMZ and are able to methylate DNA generating O6-methylguanine adducts, but unlike TMZ are able at least in part to thwart MGMT- and MMR-mediated resistance.

Keywords: glioblastoma, colorectal carcinoma, O6-methylguanine-DNA methyltransferase, apoptosis, DNA adducts
INTRODUCTION

Temozolomide (TMZ), an oral alkylating agent, has been administered in conjunction with radiation as the standard of care for glioblastoma multiforme (GBM) treatment (1). TMZ is an imidazotetrazine prodrug that is able to cross the blood–brain barrier (BBB) (2). Under normal physiological conditions, TMZ spontaneously hydrolyzes to form the active intermediate 3-methyl-(triazen-1-yl) imidazole-4-carboxamide (MTIC). MTIC rapidly breaks down to form the reactive methylidiazonium ion (diazomethane) which reacts with nucleophilic groups on DNA, resulting in DNA methylation (3). Approximately 70% of the methyl groups are located on the N7 of guanine (N7-G), 10% on N3-adenine (N3-A), and 5% at O6-guanine (O6-G) sites (2, 3). Interestingly, TMZ exerts cytotoxicity mainly through O6-methylguanosine (O6-MeG) which triggers futile cycles of mismatch repair (MMR), stalled replication forks and lethal DNA double-strand breaks, while N7- and N3-methyl purines are rapidly repaired by base excision repair (BER) (4, 5). However, O6-MeG lesions can be repaired by O6-methyl-guanine DNA methyltransferase (MGMT), a DNA repair protein that removes alkyl groups located at the O6-position of guanine (6). Thus, response to TMZ requires low MGMT expression and intact MMR (7, 8).

Resistance to TMZ conferred by MGMT and tolerance to O6-MeG in the presence of defective MMR limits TMZ clinical applications. Therefore, strategies have been devised to reduce resistance and enhance response to TMZ, including inhibition of DNA repair mechanisms which contribute to TMZ resistance. For example, combining MGMT inhibitors, which consume MGMT and prevent O6-MeG repair, with TMZ sensitizes tumors to TMZ treatment (9). However, myelosuppression limits the use of MGMT inhibitors and alkylating agent combination chemotherapy (10). Other DNA repair (BER) protein inhibitors have been used in combination with TMZ to treat cancer, such as poly ADP-ribose polymerase (PARP) inhibitors. Although PARP inhibitors (in combination with TMZ) are better tolerated than MGMT inhibitors, myelosuppression, and liver toxicity still cause clinical concern (11, 12).

An alternative strategy is the development of TMZ analogs which can overcome TMZ-resistance. A series of TMZ derivatives has been synthesized and the antitumor activity was investigated in vitro. N3-substituted TMZ analogs were developed and several derivatives exhibited an activity against TMZ-resistant tumor cells in vitro (13–16). In contrast, C8-substituted TMZ analogs have rarely been reported and compounds mechanisms of action remain unclear (17). In this study, the anti-tumor effects of two novel C8-substituted TMZ derivatives have been investigated in TMZ-resistant tumor models in vitro. The C8 carboxamide was replaced by imidazolyl (377) and methylimidazole (465) groups, respectively (Figure 1). 377 and 465 analogs demonstrated good antitumor activity against MGMT overexpressing glioma T98G and MMR deficient colorectal carcinoma HCT116 cell lines. Moreover, 377 and 465 were able to arrest the cell cycle at G2/M, evoke DNA damage, and trigger apoptosis in T98G GBM and HCT116 CRC cells, irrespective of MGMT and MMR status. The mechanism by which analog 377 exacts DNA damage, and specific DNA lesions produced have been identified. Like TMZ, analog 377 ring-opens and hydrolyzes under physiological conditions leading to DNA adducts formation N7-methylguanine (N7-MeG), O6-methylguanine (O6-MeG), N3-methyladenine (N3-MeA), N3-methylthymine (N3-MeT), and N3-methylcytidine (N3-MeC) deoxynucleotides.

MATERIALS AND METHODS

Chemicals

TMZ was provided by Schering-Plow Research Institute (Kenilworth, NJ, USA). New analogs, synthesized at Pharminox Ltd, BioCity, Nottingham, UK, were prepared as 100 mM stock solutions in dimethyl sulfoxide (DMSO) and stored at −20°C. Reagents, unless specified otherwise, originated from Sigma-Aldrich Ltd.

Cell Lines and Culture Conditions

SNB19V (vector) and isogenic MGMT-transfected SNB19M human GBM cell lines were provided by Schering-Plow. Cells were cultured in RPMI 1640 medium supplemented with 2% glutamine, 1% non-essential amino acids, 50 µg/ml gentamicin, 400 g/ml G418 (geneticin), and 10% fetal bovine serum (FBS). HCT116 (hMLH1-) and HT29 CRC cells obtained from the American Type Culture Collection (ATCC), were maintained in RPMI 1640 medium supplemented with 10% FBS. T98G GBM cells (sourced from the ATCC) were grown in DMEM medium supplemented with 10% FBS. Cells were incubated in a humidified atmosphere of 95% air and 5% CO2 at 37°C.

MTT Assay

Cells were seeded into wells at a density of 4 × 103 per well in 96-well plates and allowed to attach overnight. TMZ, 377, or 465 dilutions were prepared in culture medium from 100 mM stock solutions and final well-concentrations between 0.1 and 1,000 µM were achieved (n = 3). Following 3 days of incubation (37°C, 5% CO2). Sterile-filtered 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (20 µl; 5 mg/ml in phosphate buffered saline) was added to each well (final concentration 0.4 mg/ml). Plates were re-incubated for 4 h allowing metabolism of MTT by viable cells to insoluble formazan crystals. Medium and unconverted MTT were aspirated and DMSO (150 µl) was added to each well
to ensure complete formazan solubilization, absorbance was read on a BioTek Synergy H1 microplate reader (490 nm). Compounds concentrations causing 50% inhibition (IC_{50}) values were calculated by interpolation.

**Clonogenic Assay**

Exponentially growing cells were seeded in triplicate at a density of 300 cells per well in 6-well plates and allowed to attach overnight before introduction of TMZ (final concentrations 5, 10, 50, and 100 µM), 377 (final concentrations 20, 40, 60, 80, and 100 µM), 465 (final concentrations 10, 20, 30, 40, and 50 µM). Control wells received vehicle alone.

After 16 h exposure, media were aspirated, cells washed, and TMZ-free media introduced. Plates were incubated for 11 days at 37°C in an atmosphere of 5% CO₂. Cells were washed (3 × in phosphate buffered saline), fixed with pre-chilled methanol (100%; 20 min), stained with 0.5% methylene blue in 1:1 methanol/H₂O (v/v) for 10 min, washed thoroughly in dH₂O and air-dried. Cell colonies containing > 50 cells were counted and IC_{50} values were calculated by interpolation.

**Detection of γ-H2AX Foci**

HCT116 and T98G cells (2 × 10⁵) were seeded onto coverslips in 6-well plates and incubated overnight, before being exposed to 377 (50 and 100 µM) and 465 (20 and 50 µM) for 3, 6, 9, 12, and 24 h. Cells were fixed with ice cold acetone, rinsed with PBS and blocked with 3% BSA and treated with 0.3% Triton-X in PBS for 30 min at room temperature. Cells were incubated with primary antibody (1° Ab) recognizing phosphorylated H2AX (γH2AX; Cell Signaling; overnight at 4°C), then fluorescence-conjugated Alexa Fluor 488 secondary (2° Ab) (Life technologies; 8 µg/ml diluted in antibody dilution buffer) for 60 min at room temperature protected from light. Nuclei were stained with 0.1 µg/ml DAPI. Cells were observed by immunofluorescence microscopy (Nikon, Japan; original magnification 100 ×) and images captured.

**Pulsed-Field Gel Electrophoresis**

Cells (2 × 10⁵) were seeded onto coverslips and incubated overnight before treatment with 100 µM TMZ, 100 µM 377, and 50 µM 465 for 24 and 48 h. Cells (6 × 10⁴) were collected from each sample and small agarose plugs embedded with cells were prepared. The small plugs were then digested with Proteinase K reaction buffer (10 mM Tris, 20 mM NaCl, 50 mM EDTA, and 1 mg/ml Proteinase K; 50°C, 48 h). The plugs were washed four times in 50 ml of wash buffer (20 mM Tris, pH 8.8, 50 mM EDTA) for 30 min each at room temperature. DNA fragments in plugs were separated on 1% w/v agarose in 0.5 × Tris/borate/ethylenediaminetetraacetic acid (TBE) buffer at 14°C using a CHEF DR III apparatus (Bio-Rad) with 6 V/cm, pulsed from 60 to 120 s for 24 h. The gels were stained with ethidium bromide (EB). Images were recorded using a gel imager (BIOGEN).
incubator. JC-10 monomers and J-aggregates were detected by flow cytometry on FL1 and FL2 channels, respectively. Data were analyzed using C6 software.

Sample Extraction and Purification
Calf thymus DNA (40 µl; 0.2 mg) and 40 µl 377 (0.2 mg) were dissolved in 120 µl NaCl (15 mM) and incubated in 37°C for 24 h. The reaction mixture was then cooled to room temperature, and extracted with 250 µl diethyl ether 4 × with centrifugation. The extracted DNA was precipitated with 100 µl 3 M sodium acetate solution (pH 5.2) and 1 ml ice-cold ethanol. The solution was then put on ice for 30 min and centrifuged at 4°C at 10,000 g for 15 min. The resulting DNA pellet was washed twice with 100 µl ethanol (70%) and dried under vacuum. The dried DNA pellet was re-dissolved in 100 µl 2 mM magnesium acetate solution, then 2 µl 50 units benzonase enzyme were added before incubation at 37°C for 4 h. Nuclease S1 enzyme (10 µl; 200 units) was added, and the solution was further incubated at 37°C for 4 h. Finally, solid-phase extraction (SPE) was carried out for these samples as follows: the cartridges were conditioned with 3 ml methanol and 2 ml 15 mM NaCl (pH 7.4). After sample absorption, cartridges were washed with 3 ml 15 mM NaCl to remove unmodified nucleotides and modified nucleotides were eluted from the cartridges with 2 ml methanol. The solvent was removed in a vacuum centrifuge and the dried residues were re-dissolved in 100 µl purified water.

HPLC
The LC system consisted of an Agilent (USA) Accela HPLC pumping system, coupled with an Accela Autosampler and Degasser. Chromatographic separation of the DNA-adducts was achieved by reverse phase chromatography and gradient elution. Separation of the DNA-adducts was carried out on a Perfluorophenyl column (Phenomenex Luna, USA), at 25°C. The gradient mobile phase was prepared from 1% ethanoic acid, pH 5.5 (Eluent A) and methanol (Eluent B); gradient program: 0 min 95% A, 0–6 min up to 95% B, 6–8 min 95% B, 8–8.1 min back to 95% A, 8.1–11 min equilibration. The flow rate was 1 ml/min and the injected volume was 5 µl.

| Table 1 | MTT assay IC50 values of TMZ and C8-imidazotetrazine analogs 377 and 465 against human cancer cell lines. |
| --- | --- | --- | --- | --- |
| Cell line | MGMT | MMR | IC50 (µM) 3 days |
| --- | --- | --- | --- | --- |
| SNB19V | Proficient | 38.01 ± 16.35 | 32.96 ± 10.80 | 14.34 ± 2.92 |
| SNB19M | Proficient | 508.84 ± 142.32 | 65.92 ± 7.68 | 31.83 ± 8.66 |
| HCT116 | Proficient | 592.88 ± 16.10 | 44.23 ± 12.72 | 25.37 ± 2.21 |
| T98G | Proficient | 286.96 ± 19.61 | 62.50 ± 6.93 | 33.09 ± 3.42 |

Table 1: TMZ, 377, and 465 were dissolved in DMSO at a stock solution of 100 mM (stored at −20°C) and diluted in culture medium prior to use. IC50 values of new analogs were determined by MTT assay following 3 days of exposure and are shown as mean ± SD of three independent experiments.

| Table 2 | Clonogenic assay IC50 values of TMZ and C8-imidazotetrazine analogs 377 and 465 against human cancer cell lines. |
| --- | --- | --- | --- |
| Compound | SNB19V | SNB19M | IF* |
| --- | --- | --- | --- |
| TMZ | 32.20 ± 10.35 | 854.65 ± 142.32 | 27 |
| 377 | 17.86 ± 7.30 | > 100 | > 6 |
| 465 | 14.34 ± 2.92 | 31.83 ± 8.66 | 2 |

IC50 values of TMZ and new analogs were determined by colony-formation assay following 11 days incubation after compound treatment (16 h) and are shown as mean ± SD of three independent experiments, IF*: SNB19M IC50 value/SNB19V IC50 value.

Compound Stability Test
TMZ or 377 (20 µl; 5 mg/ml) were mixed thoroughly with 80 µl pure water to make final concentration of 5.1 mM for TMZ and 4.6 mM for 377 in a 37°C incubator. At different time points (0–48 h), samples were taken for detection, and filtered using a 13 mm 0.2 µm polytetrafluoroethylene (PTFE) needle prior to HPLC detection. The data processing was carried out with Agilent 1260 Infinity.

UPLC-Q-TOF/MS Analysis
The Agilent 6540 UPLC-Q-TOF / MS (USA) was used with electrospray ionization for DNA adducts qualitative detection. Chromatographic separation of DNA adducts was achieved by reverse phase chromatography and gradient elution. The detection conditions of UPLC were the same as those for HPLC. Analysis was performed on a triple quadrupole time of flight mass spectrometer, fitted with a heated electrospray ionization source Jet Stream operating in the positive ion mode with the following working conditions: dry gas N2 temperature of 350°C and flow rate of 9 l/min; nebulizer pressure of 40 psig; capillary voltage of 3,500 V; nozzle voltage of 1,000 V; fragmentor voltage of 135 V; secondary mass spectral collision pool voltage of 20 V. For full MS investigations, scans range from 10 to 500 m/z using a scan rate of 10 spectra/s. Finally, data processing was carried out with MassHunter software.

Statistical Analysis
Statistical significance was determined using Students’ t-test analyses. P ≤ 0.05 was considered significant.

RESULTS
Growth Inhibition
The activity of TMZ and analogs 377 and 465 was tested against a pair of isogenic human GBM cell lines: SNB19V (vector control) and SNB19M (stable MGMT transfection). TMZ was active in MGMT negative/low cell lines, with an IC50 value of 38.01 µM in SNB19V cells, but inactive in MGMT-overexpressing cells. SNB19M cell line transfected with MGMT demonstrated 13.39-fold inherent resistance to TMZ with a mean IC50 value of 508.84 µM. As can be seen in Table 1, C8-imidazolyl 377 showed anticancer activity in SNB19V and SNB19M cells with mean IC50 values of 32.96 µM and 65.92 µM, respectively. Methyl imidazole analog 465 gave IC50 values of 14.34 µM and 31.83 µM.
FIGURE 2 | C8-imidazotetrazine analogs 377 and 465 induce cancer cell DNA damage. (A) Induction of γH2AX foci in HCT116 cells following exposure to 377 and 465. HCT116 cell was treated with vehicle control, 50 µM 377 and 465 for 3, 9, 12, and 24 h; (B) Foci of treated HCT116 cells were quantified by densitometry.
in SNB19V and SNB19M cells, respectively. In addition, 377 and 465 showed good anticancer activity against the T98G GBM cell line which maintains inherently high MGMT expression, with IC_{50} values of 62.50 µM and 33.09 µM, respectively. Therefore, MGMT expression whilst conferring marked resistance to TMZ, conferred only ~2-fold resistance to 377 and 465. Furthermore, the MMR-deficient HCT116 CRC cell line, resistant to TMZ (IC_{50} values > 500 µM), responded to 377 (IC_{50} value 44.23 µM) and 465 (IC_{50} value 25.37 µM). Consistently, methylimidazole analog 456 demonstrated ~twice the potency of imidazolyl analog 377.

In vitro, the antitumor activity of TMZ derivatives was further corroborated by clonogenic assays. As shown in Table 2, compared to SNB19V cells (IC_{50} value 32.2 µM), SNB19M cells demonstrated ~7-fold inherent resistance to TMZ (IC_{50} value 854.65 µM) following 11 days exposure of SNB19V and SNB19M cells to TMZ. Compared to SNB19V cells (IC_{50} value 17.86 µM), SNB19M cells showed > 6-fold resistance to C8-imidazol analog 377 (IC_{50} value > 100 µM). C8-methylimidazole analog 465 exerted potent inhibition of colony formation in SNB19V cells (IC_{50} value 14.34 µM) and moreover, potent anti-clonogenic activity against MGMT-expressing SNB19M cells (IC_{50} 31.83 µM).

These results indicate that novel imidazolyl and methylimidazole imidazotetrazinones 377 and 465 inhibit the growth of tumor cells irrespective of MGMT and MMR; of note, 465 demonstrated superior activity (~2-fold) against TMZ-resistant cells guiding compound concentration selection in further experiments.

Generation of DNA Double-Strand Breaks by Imidazotetrazine Analogs

TMZ generates O6-MeG adducts which trigger futile cycles of mismatch repair (MMR) in MMR-proficient cells that ultimately lead to lethal DNA double-strand breaks (DSBs). DSBs induce rapid phosphorylation of Ser139 at the carboxy terminus of histone H2AX, namely γH2AX; γH2AX has become the "gold standard" marker of DNA DSBs. In order to determine whether 377 and 465 evoke DNA DSBs, the formation of γH2AX foci was examined in HCT116 cells treated with 377 (50 and 100 µM) and 465 (20 and 50 µM) and visualized by immunofluorescence microscopy following 3, 9, 12, and 24 h exposure. Representative foci in HCT116 cells are shown in Figure 2A and foci quantification of treated cells is shown in Figure 2B. As demonstrated, new analogs 377 (50 and 100 µM) and 465 (20 and 50 µM) induce time- and concentration-dependent DNA DSBs in HCT116 cells. In addition, T98G cells were treated with 100 µM 377 and 465 for 3, 6, and 12 h, cellular γH2AX foci increased time-dependently (Figures 2C,D).

Moreover, pulsed-field gel electrophoresis (PFGE) was adopted to detect genomic DNA DSBs. HCT116 cells were treated with TMZ (100 µM), 377 (100 µM), 465 (50 µM), and DDP (cisplatin, 10 µM; positive control) for 24 and 48 h, and disruption of genomic DNA was detected by PFGE (Figure 2E). TMZ and 377 both induced DSBs in HCT116 cells and the extent of genomic DNA breakage increased with time. Furthermore, global γH2AX expression was examined by Western blot following exposure of T98G cells to TMZ (100 µM), 377 (50 and 100 µM), and 465 (50 and 100 µM) for 6, 12, 24, and 48 h. As shown in Figure 2F, TMZ only slightly increased the expression of γH2AX in T98G cells, whereas, the same concentration of 377 and 465 caused more extensive, time-dependent γH2AX expression. Together these data indicate that new analogs 377 and 465 cause DNA damage in TMZ-resistant cells.

It is known that the TMZ analog mitozolomide results in DNA cross-linking (18), which causes severe and unpredictable bone marrow suppression (19). Therefore, we examined by alkaline gel electrophoresis whether the TMZ derivatives caused DNA cross-links. Double-stranded DNA was treated with 1, 10, and 20 µM TMZ, 377, and 465, DDP (cisplatin, 10 and 100 µM) was used as a positive control; as Figure 2G demonstrates, imidazotetrazine analogs TMZ, 377, and 465 did not lead to formation of DNA cross-links.

Cell Cycle Perturbation by Imidazotetrazine Analogs

Futile DNA repair cycles triggered by TMZ result in cell cycle arrest in the absence of MGMT and the presence of MMR. To compare the effects of TMZ and analogs on cell cycle progression, DNA flow-cytometric analyses of SNB19V and SNB19M cells following exposure to agents (24–96 h) were performed. After 48 h treatment with 100 µM TMZ, 28.7% of the SNB19V cells arrested at G2/M (compared with 17.7% of control cells in G2/M; Figure 3A). Further significant (P < 0.01) and prolonged accumulation of DNA in G2/M phases was observed after 72 and 96 h of exposure (31.8 and 48.5%, respectively). In contrast, 100 µM TMZ failed to perturb SNB19M cell cycle, a result attributed to competent MGMT activity (Figure 3A).

Exposure of SNB19V cells to 377 (50 µM) significantly (P < 0.001) increased S-G2/M events by > 15% during the first 24 h period, persistent G2/M accumulation was maintained from 48 to 96 h, and a small pre-G1 peak indicative of apoptosis induction emerged; 6.6% pre-G1 phase at 96 h (0.9% pre-G1 in control) (Figure 3B). Compared to SNB19V cells, SNB19M cells also exhibited significant (P < 0.001) S-G2/M arrest at 24 h exposure, but the S-G2/M block was transient—reversing ≥ 48 h.
FIGURE 3 | demonstrating the effects of TMZ (A), 377 (B), and 465 (C) on cell cycle progression. Following desired exposure periods, cellular DNA was stained with propidium iodide and analyzed by flow cytometry. Control samples were treated with equal volume DMSO. For each sample, 10,000 events were recorded and experiments were performed in triplicate; n ≥ 3 independent trials.

(Figure 3B). Cell cycle perturbations caused by 377 (100 µM) in both SNB19V and SNB19M were similar to those elicited by 50 µM 377.

SNB19V and SNB19M cells exposed to 465 (50 µM) revealed obvious (P < 0.01) S-G2/M arrest at 24 h. Further significant (P < 0.001) and prolonged accumulation of G2/M phase events was observed from 48 to 72 h (38.1 and 37.3% in SNB19V; 53.0 and 48.2% in SNB19M populations, respectively; Figure 3C). The percentage of the cell population in G2/M was higher in SNB19M cells than SNB19V cells, 53.0% compared to 38.1% at 48 h and 48.2% compared to 37.3% at 72 h. Analog 465 (20 µM) minimally perturbed SNB19V and SNB19M cell cycles (Figure 3C). The effect of TMZ derivative 465 on the cycle of MMR-deficient HCT116 cells was also examined. It was evident that events in G2/M accrued at both 48 and 72 h (50 µM 465) while 50 µM TMZ did not interfere with the cell cycle (Figure S1). These data indicate that TMZ analogs 377 and 465 cause cell cycle perturbation in TMZ-resistant cells.

Induction of Apoptosis by Imidazotetrazine Analogs

In order to further investigate the cellular effects of 377 and 465, we characterized their impact on cell death at the molecular level. Lysates from compound-treated cells were subjected to Western blot analyses for expression of two apoptosis markers, caspase 3 activation, and cleaved PARP. Initially, HCT116 cells were treated with the same concentration (50 µM) of TMZ and its derivatives for 48 h. As shown in Figure S2, we found that only 465 induced PARP cleavage. HCT116 cells were subsequently treated with 20 and 50 µM 465 for 24, 48, and 72 h. 465 induced apoptosis in a time- and concentration-dependent manner: 20 µM 465 analog induced PARP cleavage ≥ 48 h, however, cleaved PARP was detected in lysates of cells treated with 50 µM 465 ≥ 24 h (Figure 4A). In addition, 50 µM 465 also led to cleaved caspase (48 and 72 h). In addition, MGMT-overexpressing T98G cells were also exposed to 100 µM TMZ, 50, and 100 µM 377 and 465 for 24 and 48 h. As shown in Figure 4B, neither significant caspase 3 nor PARP cleavage were induced by TMZ, 377, or 465 cells after 24 h. However, cleaved PARP was detected ≥ 48 h by 50 µM 377 and 465, and 100 µM TMZ. These data indicate that analogs 377 and 465 cause apoptosis in TMZ-resistant cells.

To corroborate this conclusion, changes in HCT116 cells mitochondrial membrane potential was determined after exposure of cells to 465 (20). As shown in Figure 4C, when HCT116 cells were treated with 10, 20, and 50 µM 465 for 9 h; the JC-10 monomer signals increased
Yang et al. Imidazotetrazine Analogs Overcome Temozolomide Resistance

FIGURE 4 | Induction of apoptosis by C8-imidazotetrazine analogs 377 and 465. Detection of apoptosis proteins (PARP and caspase 3) by Western blot in (A) HCT116 cells and (B) T98G cells following treatment of cells with different concentrations TMZ, 377, or 465 for 24, 48, or/and 72 h. (C) HCT116 cells were dye-loaded with JC-10 dye-loading solution along with 10, 20, and 50 µM 465 for 9 h. The fluorescent intensities for both J-aggregates and monomeric forms of JC-10 were measured by flow cytometry using FL1 (green) and FL2 (red) channels. Data were analyzed using C6 software. (D) Quantitative assessment of JC-10 monomer signals. (*P < 0.05, **P < 0.01).

significantly (P < 0.05) in a concentration-dependent manner (Figures 4C,D).

Hydrolysis of Imidazotetrazine Analog 377
Under physiological conditions, TMZ is able to hydrolyze to form MTIC which rapidly breaks down to form diazomethane and 5-aminomidazole-4-carboxamide (AIC); diazomethane causes methylation of DNA, leading to cell death. We hypothesize that 377 could ring-open and alkylate DNA like TMZ, resulting in DNA damage to tumor cells and subsequent apoptosis. Analog 377 was dissolved in water, incubated at 37°C and analyzed by HPLC. As shown in Figure 5A, three peaks were observed at retention times tR = 2.12 min, tR = 2.43 min, and tR = 4.43 min. The hydrolyzate of 377 was then identified using a highly sensitive UPLC-Q-TOF/MS. As shown in Figure 5B, the absorption peaks can be detected in the total ion flow chromatogram. They were the intermediate, metabolite and absorption peaks of 377. The structures were assigned on the basis of UPLC-Q-TOF/MS data. The absorption peak of 377 had a retention time of 3.568 min and an ion [M+H]+ at m/z 218.0786, indicating that the molecular formula was C8H7N7O. The intermediate had a retention time of 1.448 min and an ion [M+H]+ at m/z 192.0992, indicating that the molecular formula was C7H6N7. The metabolite had a retention time of 1.999 min and exhibited an ion [M+H]+ at m/z 150.0772, indicating that the molecular formula was C6H5N5 (Figures 5C–E). Therefore, we speculate that (similar to TMZ) 377 can undergo hydrolysis. These data indicate that 377 is rapidly hydrolyzed to form the intermediate 5-(3-methyltriazen-1-yl) imidazole-4-imidazole under physiological conditions, and then undergoes further hydrolysis to form 5-aminimidazole-4-imidazole and a diazonium ion (Figure 5F).

Stability of Imidazotetrazine Analog 377
The stability of 377 in H2O was monitored by HPLC. TMZ or 377 solutions (1 mg/ml) were incubated at 37°C for 0–48 h. As shown in Figure 6A, TMZ was readily hydrolyzed at 37°C, and almost completely hydrolyzed to form AIC at 48 h. The intermediate product MTIC was very unstable and the absorption of MTIC could not be detected by UV detector. The peak area of TMZ decreased from 2,758 mAU∗s to 475 mAU∗s at 37°C between
0 and 24 h, reaching 50% after 10 h. The absorption peak of TMZ could not be detected at 48 h, but the absorption peak of AIC increased with time (Figure 6B). However, the peak of 377 at 37°C decreased from 279 mAU*s to 0 mAU*s over 20 h, reducing to 50% after 6 h. The peak of 377 could not be observed at 20 h (Figures 6C,D), correspondingly, the peak areas of the intermediate and hydrolysate accumulated over time (0–20 h): from 87 mAU*s to 518 mAU*s and from 21 to 2,491 mAU*s, respectively. These data suggest that 377 hydrolyzes more rapidly than TMZ, and the intermediate is more stable than that of TMZ (MTIC).

### DNA Adducts of Imidazotetrazine Analog 377

To investigate DNA adducts of 377, calf thymus DNA (ctDNA) was incubated with 377 in vitro and the resulting modifications were enzymatically cleaved with benzonase and nuclease S1. Compared with the chromatograms of 377 and ctDNA alone, four new absorption peaks were observed at retention times $t_R = 5.241$, $t_R = 5.418$, $t_R = 5.702$, and $t_R = 5.885$ by HPLC analysis (Figures 7A–C). We speculated that DNA adducts may be formed. As described above and shown in Figure 5F, 377 can ring-open to form an intermediate which then further breaks down to a reactive diazonium, we posit that the diazonium will alkylate DNA. Therefore, UPLC-Q-TOF/MS was used to analyze the structures of DNA adducts. As shown in Figure 8A, new absorption peaks in the total ion current profile and the UV absorption pattern are apparent.

Upon analysis, the following deoxynucleotide adducts were identified: N3-MeA (tR = 2.305 min), [M+H]$^+$ ion at m/z 152.0577, molecular formula $C_6H_9N_3O$; N7-MeG (tR = 1.654 min), [M+H]$^+$ ion at m/z 168.0877, molecular formula $C_6H_9N_3O$, which gave rise to a fragment ion at m/z 151.3526 and showed the loss of $-CH_3$; O6-MeG (tR = 1.654 min), [M+H]$^+$ ion at m/z 168.0880, molecular formula $C_6H_9N_3O$–gave rise to a weak fragment ion at m/z 151.2436 but demonstrated no loss of $-CH_3$, thus is the basis for the distinction between N7-MeG and O6-MeG; N3-MeT (tR = 5.043 min), [M+H]$^+$ ion at m/z 141.0663, molecular formula $C_6H_8N_3O_2$; N3-MeC (tR = 7.547 min), [M+H]$^+$ ion at m/z 324.0930, molecular formula $C_6H_{18}N_3O_7P$; N3-MeA (tR = 7.012 min), [M+H]$^+$ ion at m/z 348.1042, molecular formula $C_{11}H_{18}N_3O_6P$ (Figures 8B–F).
DISCUSSION

Temozolomide plays a key role in GBM therapy; indeed, radiotherapy, and concomitant and adjuvant chemotherapy with temozolomide is the standard of care for this devastating malignancy. TMZ has also been used in the treatment of other cancers (e.g., malignant melanoma) (21), but the ultimate benefit is limited by inherent, or emergence of resistance. Expression of the DNA repair protein MGMT accounts for TMZ resistance; inactivation or down-regulation of MMR leads to acquired tolerance to TMZ-induced lesions (2, 7) and moreover, TMZ exposure can promote a hypermutator phenotype (22). Therefore, developing new TMZ derivatives which can overcome TMZ-resistance may provide significant therapeutic advantage.

A variety of TMZ derivatives has been previously reported (13–17, 23–28). The most common modification sites for these analogs are at the N3 or C8 positions of TMZ. Among them, N3-modified TMZ analogs can be divided into two categories: one class of derivatives involves incorporation of groups to link two TMZ molecules through the N3 site, for example, derivatives DP68 are two TMZ molecules linked together by methylaniline. DP68 binds two DNA strands together by hydrolysis to cross-link the DNA and thus kill the cells (23). Another class of analogs results from replacement of the methyl group at the N3 position with substituents, such as chloromethyl or propargyl. These derivatives allow the new group to alkylate DNA, thereby exerting a cytotoxic effect (13, 14). In addition, C8-modified TMZ analogs can also be divided into two categories: one class may be derived through conjugation of two TMZ molecules through the C8 position. For example, the analog 2T-P400 links two TMZs by polyethylene glycol, thereby enhancing the solubility and stability of TMZ (24). Another type of derivative may be formed following replacement of the C8 carboxamide group of TMZ by another group. For instance, NEO212 is a covalent bond of perillyl alcohol to the C8 site of TMZ, thereby enhancing the efficacy of TMZ (25–27), while TMZ hexyl ester which incorporates a hexyl ester bound to the C8 site of TMZ can improve TMZ skin delivery and antitumor potency (28). In addition, other C8-substituted derivatives such as 8-cyano-imidazotetrazine and 8-thiotemozolomide have been developed, but their antitumor mechanism(s) remain to be defined (17).

In this study, the anti-cancer activity of two novel C8-substituted TMZ analogs C8 imidazolyl (377) and C8 methyl imidazole (465) has been evaluated. Isogenic GBM cell
Yang et al. Imidazotetrazine Analogs Overcome Temozolomide Resistance

FIGURE 7 | Chromatogram of 377 with ctDNA by HPLC. (A) Chromatogram of 377. (B) Chromatogram of ctDNA. (C) Chromatogram of 377 with ctDNA.

lines, SNB19V (vector control), and SNB19M (stable MGMT transfection), were used to detect the activity of TMZ and its derivatives. TMZ is active in the MGMT-low cell line, with a mean IC\textsubscript{50} value of 38.01\,\mu M, but inactive in MGMT-overexpressing SNB19M cells, with a mean IC\textsubscript{50} value of 508.84\,\mu M. SNB19M cells overexpressing MGMT revealed 13-fold resistance to TMZ (Table 1). However, TMZ analogs 377 and 465 demonstrate activity in SNB19 GBM cell lines, irrespective of MGMT activity. Moreover, relative to TMZ, 377, and 465 show greater potency (~5–24-fold) in MGMT overexpressing glioma T98G and MMR deficient CRC HCT116 cells.

These results may indicate that C8 imidazolyl or methylimidazole confer properties such as greater stability or more efficient delivery than the carboxamide on the imidazotetrazine. Intriguingly, in clonogenic assays, after brief (16 h) exposure of cells to imidazotetrazine analogs, we found that the IC\textsubscript{50} value of 377 against SNB19M cells was at least 6-fold greater than that in SNB19V cells, while the activity of 465 against SNB19M (compared with SNB19V) cells was only 2-fold greater (Table 2). These data suggest that the lesions imparted by 377 can be repaired by MGMT over time, whereas inclusion of a methyl group within the C8 imidazolyl (465), imparts structural changes that lead to more stable DNA adducts, less susceptible to MGMT repair.

TMZ exerts cytotoxicity primarily through O6-MeG, which triggers ineffective cycles of MMR, stalled replication forks and lethal DNA double-strand breaks, leading to cell death by autophagy or apoptosis (2, 4). We found through immunofluorescence, that new analogs 377 and 465 can induce DSB in T98G and HCT116 cells after 6 h treatments (Figures 2A,C). Further study found that TMZ and analogs could induce DSBs in HCT116 and T98G cells. The lower concentration of 465 (50\,\mu M) in HCT116 cells can result in DNA damage equal to, or greater than that inflicted by the higher concentration (100\,\mu M) of TMZ and 377 (Figure 2D). γH2AX

Frontiers in Oncology | www.frontiersin.org 11 June 2019 | Volume 9 | Article 485
expression in T98G cells was also examined; compared with TMZ, the same concentration of 377 and 465 can upregulate the expression of γH2AX (Figure 2E). Moreover, we found that unlike the TMZ analog mitozolomide, TMZ derivatives 377 and 465 did not produce DNA cross-links (Figure 2F) that can cause serious side effects such as myelosuppression. These results indicate that analogs 377 and 465 can evoke DNA damage in TMZ-resistant cells without leading to DNA cross-linking. We found that TMZ analogs 377 and 465 can lead to G2/M arrest irrespective of MGMT status, and 465 had a greater effect on the cell cycle of MGMT highly-expressing SNB19M cells (Figure 3). Analog 465 also caused G2/M block in HCT116 cells (Figure S1). In addition, combined evidence strongly suggests that C8 analogs 377 and 454 induce apoptotic cell death in TMZ-resistant cells (Figure 3). P ARP cleavage, caspase activation, and enhanced JC-10 monomer detection (Figure 4). Mitochondrial membrane potential changes indicate that TMZ derivatives may lead to apoptosis dependent on mitochondrial pathways. Together, these data demonstrate that novel C8-substituted TMZ analogs can circumvent TMZ resistance in CRC and GBM cells.

Experiments were undertaken to determine mechanistic activation of C8 analogs, and whether (like TMZ) they act as prodrug vehicles ultimately delivering a toxic methyl lesion to O6-guanine. We established that TMZ analog 377 ring-opens and is rapidly hydrolyzed under physiological conditions to form the intermediate 5-(3-methyltriazen-1-yl) imidazole-4-imidazole (MTII), MTII possesses markedly greater stability than MTIC (the hydrolysis intermediate of TMZ), producing 5-aminoimidazole-4-imidazole and diazonium (Figure 5F). The reactive diazonium produces methylated DNA lesions at multiple sites including N3-MeA, N7-MeG, and O6-MeG (Figures 8B,C). Thus, as shown in (Figures 6A–C), 377 hydrolysis is faster.
than TMZ, and the intermediate is more stable which may explain why 377 exerts activity in TMZ-tolerant or -resistant HCT116 and T98G cells. However, long term, the damage accrued from exposure of cells to 377 can be repaired by MGMT and 377 activity is therefore attenuated (Table 2, Figure 3B), as supported by clonogenic assays. Therefore, replacement of C8 carboxamide by imidazolyl (377) and methyl imidazole (465) may enhance stability of intermediates which might induce DNA damage and apoptosis in MGMT overexpressing and MMR deficient CRC cells. Unfortunately, analyses of stability, and DNA adduct formation by analog 465 was thwarted by precipitation which occurred during incubation of 465 with ctDNA.

In summary, novel C8-substituted TMZ analogs 377 and 465 elicit in vitro antitumor activity irrespective of MGMT and MMR status. DNA DSBs were generated in MGMT-overexpressing glioma SNB19M and T98G cells and MMR deficient CRC HCT116 cells. TMZ derivatives perturbed and arrested SNB19V and SNB19M cell cycle progression. Moreover, compared to TMZ, analogs 377, and 465 were able to induce more extensive apoptosis in HCT116 and T98G cells. Similar to TMZ, analog 377 undergoes to ring opening and hydrolysis leading to DNA adducts formation which likely underlies the anticancer effects. These analogs may offer potential for TMZ-resistant GBM and broader spectrum malignancies.

DATA AVAILABILITY
All datasets generated for this study are included in the manuscript and/or the Supplementary Files.

REFERENCES
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al., European organisation for R, treatment of cancer brain T, radiotherapy G and National Cancer Institute of Canada clinical trials G. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987–96. doi: 10.1056/NEJMoa043330

AUTHOR CONTRIBUTIONS
JZ designed the experiment. ZY, DW, and XD performed the experiment and analyzed data. YL wrote the manuscript. JZ, MS, and TB reviewed and revised the manuscript. YL provided technical and material support.

CONTRIBUTION TO THE FIELD STATEMENT
Temozolomide (TMZ) is the standard of care chemotherapeutic agent used in the treatment of glioblastoma multiforme, however, the intrinsic and acquired resistance limit its clinic application. Developing the new derivatives that can overcome DNA repair is necessary. We synthesized a series of new analogs with modifications at C-8 and N-3 positions, and investigated their activity and mechanism of action. It was found some compounds exhibit anticancer activity superior to TMZ, irrespective of MGMT and MMR.

FUNDING
Financial support for all work described herein was provided by the National Natural Science Foundation of China (No. 81260501; 81560601).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.00485/full#supplementary-material

Supplementary Files
8. Garelnabi EA, Pletsas D, Li L, Kiakos K, Karodia N, Hartley JA, et al. Strategy for imidazotetrazine prodrugs with anticancer activity independent of MGMT and MMR. ACS Med Chem Lett. (2012) 3:965–8. doi: 10.1021/ml300132t
9. Wedge SR, Porteous JK and Newlands ES. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer. (1996) 74:1030–6. doi: 10.1038/bj.1996.485
10. Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, et al. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a pediatric brain tumor consortium study. J Neurooncol. (2012) 106:643–9. doi: 10.1007/s11060-011-0709-z
11. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MB, et al. A phase II trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. (2009) 27:756–63. doi: 10.1080/07357900802709159
12. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. (2008) 14:7917–23. doi: 10.1158/1078-0432.CCR-08-1223
13. Zhang J, Stevens ME, Hummersone M, Madhusudan S, Laughton CA and Bradshaw TD. Certain imidazotetrazines escape O6-alkylguanine-DNA methyltransferase and mismatch repair. Oncolytics. (2011) 80:195–207. doi: 10.1159/000327837
Yang J, Hummersone M, Matthews CS, Stevens MF and Bradshaw TD.  
N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. *Oncology*. (2015) 88:28–48. doi: 10.1159/000366131

15. Cousin D, Zhang J, Hummersone MG, Matthews CS, Frigerio M, Bradshaw TD et al. Antitumor imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome resistance in human glioblastoma cell lines. *MedChemComm*. (2016) 7:2332–43. doi: 10.1039/C6MD00384B

16. Cousin D, Hummersone MG, Bradshaw TD, Zhang J, Moody CJ, Foreiter MB, et al. Synthesis and growth-inhibitory activities of imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position. *MedChemComm*. (2018) 9:545–53. doi: 10.1039/C7MD00554G

17. Langnel DAF, Arrowsmith J, Stevens MFG. Antitumor imidazotetrazines. 38. New 8-substituted derivatives of the imidazo[5,1-d]-1,2,3,5-tetrazine temozolomide and mitozolomide. *ARKIVOC*. (2000) 2000:421–37. doi: 10.3998/ark.5550190.0001.324

18. Gibson NW, Hickman JA and Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. *Cancer Res*. (1984) 44:1772–5.

19. Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D and Rafferty JA. Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide. *Cancer Gene Ther*. (2000) 7:233–9. doi: 10.1038/sj.cgt.7700120

20. Lopez J and Tait SW. Mitochondrial apoptosis: killing cancer using the enemy within. *Br J Cancer*. (2015) 112:957–62. doi: 10.1038/bjc.2015.85

21. Li RH, Hou XY, Yang CS, Liu WL, Tang JQ, Liu YQ et al. Temozolomide for treating malignant melanoma. *J Coll Physicians Surg Pak*. (2015) 25:680–8.

22. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res*. (2006) 66:3987–91. doi: 10.1158/0008-5472.CAN-06-0127

23. Ramirez YP, Mladek AC, Phillips RM, Gynther M, Rautio J, Ross AH, et al. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. *Mol Cancer Ther*. (2015) 14:111–9. doi: 10.1158/1535-7163.MCT-14-0113

24. Li R, Tang D, Zhang J, Wu J, Wang L and Dong J. The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. *J Neurooncol*. (2014) 116:25–30. doi: 10.1007/s11060-013-1255-7

25. Chen TC, Cho HY, Wang W, Nguyen J, Jhaeveri N, Rosenstein-Sisson R, Hofman FM and Schonthal AH. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. *Cancer Lett*. (2015) 358:144–51. doi: 10.1016/j.canlet.2014.12.021

26. Cho HY, Wang W, Jhaeveri N, Lee DJ, Sharma N, Dubeau L, et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. *Mol Cancer Ther*. (2014) 13:2004–17. doi: 10.1158/1535-7163.MCT-13-0964

27. Jhaeveri N, Agasse F, Armstrong D, Peng L, Commins D, Wang W, et al. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. *Cancer Lett*. (2016) 371:240–50. doi: 10.1016/j.canlet.2015.11.040

28. Suppasansatorn P, Wang G, Conway BR, Wang W and Wang Y. Skin delivery potency and antitumor activities of temozolomide ester prodrugs. *Cancer Lett*. (2006) 244:42–52. doi: 10.1016/j.canlet.2005.11.029

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Yang, Wei, Dai, Stevens, Bradshaw, Luo and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*